Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | NAMPT | P43490 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | STS | P08842 | 4/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.47 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15535113 | 0.92 | KDM4E (0.50) | KDM4EMAPTTHRBNAMPTMEN1 | |
| SCHEMBL15534541 | 0.92 | PDE4B (0.54) | KDM4EMAPTTHRBMEN1KMT2A | |
| SCHEMBL25762585 | 0.88 | GPR119 (0.56) | KDM4EMAPTTHRBNAMPTMEN1 | |
| SCHEMBL15535023 | 0.86 | MEN1 (0.42) | KDM4EMAPTTHRBMEN1KMT2A | |
| SCHEMBL31224355 | 0.86 | PDE4B (0.47) | KDM4EMAPTTHRBMEN1KMT2A | |
| SCHEMBL14239639 | 0.85 | GPR119 (0.50) | KDM4EMAPTTHRBNAMPTMEN1 | |
| SCHEMBL19703140 | 0.84 | MAPT (0.54) | KDM4EMAPTTHRBNAMPTMEN1 | |
| SCHEMBL16220348 | 0.83 | KDM4E (0.52) | KDM4EMAPTTHRBMEN1KMT2A | |
| SCHEMBL30178932 | 0.82 | DDB1 (0.55) | KDM4EMAPTTHRBNAMPTMEN1 | |
| SCHEMBL14239669 | 0.82 | MAPT (0.50) | KDM4EMAPTTHRBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2991978-B1 | BIHETEROARYL COMPOUNDS AND USES THEREOF | F HOFFMANN LA ROCHE SA (CH) | 2025-08-20 | — | — | EP | disclosed |
| US-11129832-B2 | Biheteroaryl compounds and uses thereof | GENENTECH, INC. (US) | 2021-09-28 | — | — | US | disclosed |
| US-11129832-B2 | Biheteroaryl compounds and uses thereof | GENENTECH, INC. (US) | 2021-09-28 | — | — | US | disclosed |
| US-10774064-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-10774064-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20200188397-A1 | BIHETEROARYL COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2020-06-18 | — | — | US | disclosed |
| US-20200188397-A1 | BIHETEROARYL COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2020-06-18 | — | — | US | disclosed |
| US-20200171029-A1 | BIHETEROARYL COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2020-06-04 | — | — | US | disclosed |
| US-20200171029-A1 | BIHETEROARYL COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2020-06-04 | — | — | US | disclosed |
| US-RE47848-E1 | Biheteroaryl compounds and uses thereof | GENENTECH, INC. (US) | 2020-02-11 | — | — | US | disclosed |
| EP-2852584-A1 | SUBSTITUTED DIPYRIDYLAMINES AND USES THEREOF | F. Hoffmann-La Roche AG (CH) | 2015-04-01 | — | — | EP | disclosed |
| US-20150080367-A1 | SUBSTITUTED DIPYRIDYLAMINES AND USES THEREOF | GENENTECH, INC. (US) | 2015-03-19 | — | — | US | disclosed |
| US-20150065504-A1 | ANTIVIRAL COMPOUNDS | ALIOS BIOPHARMA, INC. | 2015-03-05 | — | — | US | disclosed |
| US-20150065504-A1 | ANTIVIRAL COMPOUNDS | ALIOS BIOPHARMA, INC. | 2015-03-05 | — | — | US | disclosed |
| WO-2015026792-A1 | ANTIVIRAL COMPOUNDS | ALIOS BIOPHARMA, INC. (US) | 2015-02-26 | — | — | WO | disclosed |
| US-20140328805-A1 | BIHETEROARYL COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140328805-A1 | BIHETEROARYL COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140328805-A1 | BIHETEROARYL COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2014-11-06 | — | — | US | disclosed |
| WO-2014177060-A1 | BIHETEROARYL COMPOUNDS AND USES THEREOF | F.HOFFMANN-LA ROCHE AG (CH) | 2014-11-06 | — | — | WO | disclosed |
| WO-2013174780-A1 | SUBSTITUTED DIPYRIDYLAMINES AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2013-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774064-B2 | Potassium channel modulators | KCNJ11, KCNJ2, KCNJ1 | KDM4E 1648/4885MAPT 2009/4885THRB 1517/4885 |
| US-11129832-B2 | Biheteroaryl compounds and uses thereof | BCHE, SNCA, HAX1 | KDM4E 3436/4885MAPT 155/4885THRB 1954/4885 |
| US-20150080367-A1 | SUBSTITUTED DIPYRIDYLAMINES AND USES THEREOF | PDXK, PRMT1, DMPK | KDM4E 238/4885MAPT 411/4885THRB 3418/4885 |
| US-20200171029-A1 | BIHETEROARYL COMPOUNDS AND USES THEREOF | BCHE, SNCA, XDH | KDM4E 3228/4885MAPT 184/4885THRB 1901/4885 |
| US-20150065504-A1 | ANTIVIRAL COMPOUNDS | MAVS, SARS1, ZC3HAV1 | KDM4E 3737/4885MAPT 4665/4885THRB 4822/4885 |
| US-20140328805-A1 | BIHETEROARYL COMPOUNDS AND USES THEREOF | BCHE, SNCA, XDH | KDM4E 3228/4885MAPT 184/4885THRB 1901/4885 |
| US-20200188397-A1 | BIHETEROARYL COMPOUNDS AND USES THEREOF | BCHE, SNCA, HAX1 | KDM4E 3436/4885MAPT 155/4885THRB 1954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.